Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

Therapeutic Advances in Medical Oncology
Sarah J Welsh, Pippa G Corrie

Abstract

Following the discovery that nearly half of all cutaneous melanomas harbour a mutation in the BRAF gene, molecular targeted kinase inhibitors have been developed for the treatment of metastatic melanoma and have dramatically improved outcomes for those patients with BRAF mutant disease, achieving high levels of objective response and prolonging survival. Since 2011, the specific BRAF targeted agents, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have been licensed for the treatment of patients with unresectable or metastatic BRAF mutant melanoma. As with other biological targeted agents, these drugs are associated with predictable patterns of adverse events. Proactive toxicity management is important to ensure maximum treatment benefit and avoid unnecessary treatment discontinuation. We review the most common and serious adverse events associated with BRAF targeted agents and suggest management algorithms to guide practitioners in using these drugs effectively in the clinic.

References

May 25, 2011·Nature Reviews. Clinical Oncology·Antoni Ribas, Keith T Flaherty
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jan 20, 2012·The New England Journal of Medicine·Fei SuRichard Marais
Feb 24, 2012·The New England Journal of Medicine·Jeffrey A SosmanAntoni Ribas
Jun 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J RenoufPhilippe L Bedard
Jun 6, 2012·The New England Journal of Medicine·Keith T FlahertyUNKNOWN METRIC Study Group
Oct 2, 2012·The New England Journal of Medicine·Keith T FlahertyJeffrey Weber
Nov 9, 2012·The New England Journal of Medicine·Margaret K CallahanPaul B Chapman
Apr 5, 2013·The New England Journal of Medicine·Antoni RibasJedd Wolchok
May 8, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher J AnkerKenneth F Grossmann
Jun 12, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathleen M MahoneyMichael B Atkins
Aug 7, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paolo A AsciertoUwe Trefzer
Nov 6, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Miles C AndrewsJonathan Cebon

❮ Previous
Next ❯

Citations

Jan 28, 2016·The Journal of Dermatology·Masutaka Furue, Takafumi Kadono
Mar 18, 2016·Clinical Kidney Journal·Rimda WanchooVincent Launay-Vacher
Apr 5, 2016·Dermatology Research and Practice·Bilgen Gençler, Müzeyyen Gönül
Mar 5, 2016·Expert Review of Anticancer Therapy·Jennifer McLachlanSusana Banerjee
Mar 31, 2016·Expert Opinion on Pharmacotherapy·Lavinia SpainJames Larkin
Jul 5, 2016·Frontiers in Cell and Developmental Biology·Roser BuscàPhilippe Lenormand
Aug 6, 2016·Expert Opinion on Drug Metabolism & Toxicology·Daniela RizzoRiccardo Riccardi
Jul 28, 2016·Current Treatment Options in Oncology·Kim Margolin
Feb 17, 2017·Therapeutic Advances in Medical Oncology·Adrianus J de Langen, Egbert F Smit
Dec 23, 2017·Endocrine-related Cancer·Koji TsumagariEmad Kandil
Sep 27, 2018·Pediatric Blood & Cancer·Tristan KnightZhihong Joanne Wang
Nov 28, 2017·Retinal Cases & Brief Reports·Mansour RahimiDavid Sarraf
Sep 18, 2018·Current Opinion in Ophthalmology·Ramana S MoorthyEmmett T Cunningham
Mar 2, 2019·Pediatric Blood & Cancer·Hannah SongJennifer T Huang
May 18, 2019·American Society of Clinical Oncology Educational Book·Melinda YushakAndrew Poklepovic
Nov 2, 2019·Nature·Jude CanonJ Russell Lipford
Aug 1, 2019·Recent Patents on Anti-cancer Drug Discovery·Debora BasileFabio Puglisi
Jan 17, 2020·Cells·Ufuk DegirmenciJiancheng Hu
Nov 27, 2019·Journal of Cosmetic Dermatology·Athanasia VarvaresouSpyros Papageorgiou
Jun 11, 2020·International Journal of Molecular Sciences·Sathyen A PrabhuSonia V Del Rincón
Jul 2, 2020·Leukemia & Lymphoma·Gordon J RuanRonald S Go
Jul 10, 2020·Ocular Immunology and Inflammation·Ruby A ParikhMeghan K Berkenstock
Jul 22, 2020·The Journal of Infectious Diseases·Randy J McCreeryAndre C Kalil

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Software Mentioned

COMBI

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.